mitoxantrone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics; anthraquinone derivatives 1821 65271-80-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mitoxantrone
  • mitoxantrone hydrochloride
  • dihydroxyanthraquinone
  • mitoxanthrone
  • mitozantrone
  • nimitoxantron
  • mitoxantrone dihydrochloride
  • mitoxantrone HCl
An anthracenedione-derived antineoplastic agent.
  • Molecular weight: 444.49
  • Formula: C22H28N4O6
  • CLOGP: 2.24
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 8
  • TPSA: 163.18
  • ALOGS: -2.78
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.59 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.78 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.25 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 53 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1987 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 361.51 25.39 194 6203 118255 63364370
Acute myeloid leukaemia 252.34 25.39 86 6311 17061 63465564
Myelodysplastic syndrome 174.30 25.39 65 6332 16689 63465936
Pancytopenia 145.37 25.39 101 6296 96832 63385793
Sepsis 132.21 25.39 115 6282 153008 63329617
Second primary malignancy 125.22 25.39 42 6355 7911 63474714
Acute promyelocytic leukaemia 103.78 25.39 23 6374 904 63481721
Thrombocytopenia 98.35 25.39 97 6300 151060 63331565
Neutropenia 97.00 25.39 103 6294 174902 63307723
Leukaemia recurrent 90.26 25.39 22 6375 1316 63481309
Bone marrow failure 72.60 25.39 42 6355 29248 63453377
Acute myeloid leukaemia recurrent 71.54 25.39 19 6378 1604 63481021
Haemophagocytic lymphohistiocytosis 71.12 25.39 30 6367 10597 63472028
Progressive multifocal leukoencephalopathy 68.53 25.39 31 6366 12940 63469685
Bronchopulmonary aspergillosis 63.25 25.39 26 6371 8609 63474016
Febrile bone marrow aplasia 56.88 25.39 23 6374 7302 63475323
Chronic hepatitis 56.72 25.39 14 6383 882 63481743
Haematotoxicity 54.63 25.39 24 6373 9352 63473273
Strongyloidiasis 52.12 25.39 14 6383 1234 63481391
Congestive cardiomyopathy 50.04 25.39 20 6377 6162 63476463
Hypogammaglobulinaemia 47.21 25.39 20 6377 7135 63475490
Lower respiratory tract infection fungal 46.84 25.39 10 6387 329 63482296
Cardiac failure 44.96 25.39 50 6347 89092 63393533
Mucormycosis 44.53 25.39 15 6382 2856 63479769
Product use in unapproved indication 44.53 25.39 71 6326 179009 63303616
Chloroma 44.19 25.39 9 6388 234 63482391
Streptococcal bacteraemia 42.90 25.39 13 6384 1764 63480861
Graft versus host disease 41.64 25.39 18 6379 6745 63475880
Venoocclusive liver disease 40.37 25.39 16 6381 4819 63477806
Cardiomyopathy 40.36 25.39 24 6373 17560 63465065
Bone marrow infiltration 39.85 25.39 10 6387 674 63481951
Acute lymphocytic leukaemia recurrent 39.77 25.39 13 6384 2256 63480369
Abdominal wall wound 39.40 25.39 7 6390 85 63482540
Haemorrhagic adrenal infarction 38.31 25.39 6 6391 31 63482594
Respiratory failure 37.98 25.39 49 6348 101809 63380816
Multiple organ dysfunction syndrome 37.88 25.39 37 6360 56715 63425910
Myeloblast percentage decreased 36.87 25.39 6 6391 41 63482584
Refractory cytopenia with multilineage dysplasia 36.08 25.39 7 6390 141 63482484
Arthralgia 35.87 25.39 7 6390 569703 62912922
Aspergillus infection 35.47 25.39 17 6380 8076 63474549
Pain 34.26 25.39 16 6381 740612 62742013
Hepatitis E 32.46 25.39 10 6387 1434 63481191
Neoplasm progression 30.59 25.39 27 6370 36401 63446224
Stem cell transplant 30.17 25.39 10 6387 1812 63480813
Leukopenia 30.09 25.39 38 6359 77252 63405373
Bacterial sepsis 29.26 25.39 12 6385 3946 63478679
Fatigue 29.25 25.39 28 6369 888000 62594625
Stenotrophomonas infection 29.12 25.39 10 6387 2017 63480608
Cardiotoxicity 28.92 25.39 15 6382 8423 63474202
Myelofibrosis 28.70 25.39 9 6388 1368 63481257
Clostridium bacteraemia 28.02 25.39 6 6391 200 63482425
Graft versus host disease in gastrointestinal tract 28.02 25.39 11 6386 3230 63479395
Chronic myeloid leukaemia 27.81 25.39 10 6387 2308 63480317
Malignant neoplasm progression 26.76 25.39 37 6360 82084 63400541
Differentiation syndrome 26.33 25.39 8 6389 1095 63481530
Pyrexia 26.17 25.39 105 6292 470373 63012252
Guillain-Barre syndrome 26.07 25.39 11 6386 3882 63478743
Colitis 25.79 25.39 28 6369 48500 63434125
Streptococcal sepsis 25.64 25.39 9 6388 1937 63480688

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 387.97 20.96 280 7135 136569 34812947
Myelodysplastic syndrome 171.67 20.96 83 7332 19125 34930391
Acute myeloid leukaemia 145.51 20.96 73 7342 18197 34931319
Neutropenia 119.40 20.96 156 7259 156622 34792894
Septic shock 113.46 20.96 105 7310 71729 34877787
Bronchopulmonary aspergillosis 83.88 20.96 47 7368 14612 34934904
Mucormycosis 82.67 20.96 35 7380 5907 34943609
Bone marrow failure 82.54 20.96 60 7355 29193 34920323
Second primary malignancy 73.18 20.96 35 7380 7851 34941665
Fungal infection 69.85 20.96 43 7372 15892 34933624
Bacteraemia 63.84 20.96 44 7371 19673 34929843
Thrombocytopenia 51.92 20.96 107 7308 156140 34793376
Minimal residual disease 51.37 20.96 13 7402 424 34949092
Ameloblastoma 51.19 20.96 10 7405 94 34949422
Aspiration bone marrow abnormal 48.23 20.96 10 7405 130 34949386
Pneumonia fungal 46.78 20.96 25 7390 7075 34942441
Leukaemia recurrent 45.86 20.96 16 7399 1599 34947917
Multiple organ dysfunction syndrome 45.80 20.96 68 7347 76498 34873018
Hypertensive hydrocephalus 42.11 20.96 8 7407 64 34949452
Disease progression 39.42 20.96 77 7338 108000 34841516
Acute lymphocytic leukaemia recurrent 39.27 20.96 17 7398 3027 34946489
Aspergillus infection 38.84 20.96 27 7388 12227 34937289
Venoocclusive liver disease 38.77 20.96 23 7392 7943 34941573
Neoplasm progression 38.52 20.96 35 7380 23265 34926251
Cytogenetic abnormality 37.96 20.96 12 7403 883 34948633
Haematopoietic neoplasm 37.67 20.96 7 7408 49 34949467
Myelosuppression 35.95 20.96 31 7384 19234 34930282
Pancytopenia 34.93 20.96 68 7347 95089 34854427
Cardiotoxicity 34.73 20.96 19 7396 5629 34943887
Neoplasm recurrence 33.80 20.96 14 7401 2235 34947281
Mucosal inflammation 33.29 20.96 41 7374 38581 34910935
Neutropenic colitis 32.38 20.96 15 7400 3129 34946387
Cystitis haemorrhagic 31.90 20.96 18 7397 5661 34943855
Abscess fungal 31.88 20.96 8 7407 252 34949264
Sepsis 30.64 20.96 91 7324 166470 34783046
Febrile bone marrow aplasia 30.59 20.96 20 7395 8189 34941327
Gallbladder adenocarcinoma 30.37 20.96 5 7410 15 34949501
Klebsiella infection 29.89 20.96 20 7395 8511 34941005
Clostridium bacteraemia 29.26 20.96 7 7408 180 34949336
Refractory anaemia with an excess of blasts 28.13 20.96 8 7407 409 34949107
Respiratory tract infection fungal 27.76 20.96 9 7406 718 34948798
Drug ineffective 26.99 20.96 177 7238 456574 34492942
Genotoxicity 26.78 20.96 5 7410 36 34949480
Enamel anomaly 26.56 20.96 6 7409 119 34949397
Product use in unapproved indication 26.32 20.96 69 7346 117430 34832086
Osteonecrosis 25.85 20.96 23 7392 14867 34934649
Progressive multifocal leukoencephalopathy 25.20 20.96 19 7396 9745 34939771
Lymphoma 25.12 20.96 21 7394 12486 34937030
Klebsiella sepsis 25.05 20.96 11 7404 2026 34947490
Encephalopathy 24.97 20.96 34 7381 35285 34914231
Septal panniculitis 24.56 20.96 5 7410 59 34949457
Hyperammonaemic encephalopathy 23.66 20.96 11 7404 2313 34947203
Colitis 23.22 20.96 34 7381 37716 34911800
Large granular lymphocytosis 23.08 20.96 6 7409 218 34949298
Diffuse large B-cell lymphoma recurrent 23.06 20.96 12 7403 3216 34946300
Fungaemia 22.61 20.96 11 7404 2557 34946959
Gene mutation 21.96 20.96 9 7406 1399 34948117
Cerebral aspergillosis 21.81 20.96 9 7406 1423 34948093
Differentiation syndrome 21.77 20.96 9 7406 1429 34948087
Cholangitis infective 21.71 20.96 6 7409 276 34949240
Fall 21.66 20.96 8 7407 202877 34746639
Drug resistance 21.49 20.96 27 7388 25900 34923616
Tooth hypoplasia 21.19 20.96 5 7410 121 34949395
Blood culture positive 21.18 20.96 13 7402 4770 34944746

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 616.32 20.71 399 11562 230600 79501827
Acute myeloid leukaemia 377.15 20.71 150 11811 30735 79701692
Myelodysplastic syndrome 338.32 20.71 138 11823 30163 79702264
Second primary malignancy 193.69 20.71 75 11886 14275 79718152
Neutropenia 184.47 20.71 221 11740 287489 79444938
Bone marrow failure 154.64 20.71 96 11865 51011 79681416
Sepsis 130.12 20.71 180 11781 269248 79463179
Leukaemia recurrent 125.04 20.71 36 11925 2738 79729689
Thrombocytopenia 124.78 20.71 175 11786 265084 79467343
Septic shock 121.87 20.71 119 11842 122682 79609745
Pancytopenia 117.09 20.71 134 11827 165611 79566816
Bronchopulmonary aspergillosis 108.11 20.71 57 11904 22237 79710190
Mucormycosis 95.88 20.71 39 11922 8430 79723997
Acute promyelocytic leukaemia 93.16 20.71 25 11936 1466 79730961
Venoocclusive liver disease 83.53 20.71 39 11922 11732 79720695
Bacteraemia 80.35 20.71 54 11907 32770 79699657
Multiple organ dysfunction syndrome 76.17 20.71 92 11869 120154 79612273
Progressive multifocal leukoencephalopathy 76.03 20.71 44 11917 20556 79711871
Acute myeloid leukaemia recurrent 72.97 20.71 25 11936 3358 79729069
Acute lymphocytic leukaemia recurrent 72.03 20.71 27 11934 4697 79727730
Product use in unapproved indication 68.10 20.71 129 11832 250230 79482197
Fungal infection 66.55 20.71 53 11908 41695 79690732
Aspergillus infection 60.47 20.71 37 11924 19124 79713303
Febrile bone marrow aplasia 59.48 20.71 32 11929 12988 79719439
Haemophagocytic lymphohistiocytosis 58.47 20.71 38 11923 21799 79710628
Clostridium bacteraemia 57.05 20.71 13 11948 385 79732042
Cytogenetic abnormality 57.01 20.71 16 11945 1109 79731318
Ameloblastoma 54.65 20.71 10 11951 94 79732333
Neoplasm recurrence 53.22 20.71 21 11940 4193 79728234
Disease progression 51.33 20.71 96 11865 184266 79548161
Lower respiratory tract infection fungal 51.31 20.71 14 11947 874 79731553
Refractory anaemia with an excess of blasts 51.03 20.71 14 11947 892 79731535
Neoplasm progression 49.17 20.71 49 11912 51633 79680794
Chronic hepatitis 48.76 20.71 15 11946 1432 79730995
Neutropenic colitis 47.07 20.71 21 11940 5686 79726741
Haematotoxicity 46.51 20.71 29 11932 15490 79716937
Respiratory failure 46.42 20.71 91 11870 180820 79551607
Drug resistance 45.76 20.71 43 11918 42170 79690257
Myelosuppression 45.52 20.71 42 11919 40254 79692173
Cardiotoxicity 44.78 20.71 26 11935 12213 79720214
Cardiomyopathy 44.72 20.71 36 11925 28738 79703689
Differentiation syndrome 44.29 20.71 16 11945 2508 79729919
Pneumonia fungal 44.19 20.71 25 11936 11185 79721242
Klebsiella sepsis 43.87 20.71 17 11944 3235 79729192
Fatigue 41.70 20.71 47 11914 929680 78802747
Fungaemia 41.44 20.71 18 11943 4573 79727854
Hypogammaglobulinaemia 40.84 20.71 25 11936 12926 79719501
Graft versus host disease 39.86 20.71 26 11935 15000 79717427
Arthralgia 39.86 20.71 18 11943 571785 79160642
Enterococcal infection 38.88 20.71 26 11935 15634 79716793
Stem cell transplant 38.33 20.71 16 11945 3688 79728739
Pain 38.06 20.71 30 11931 703772 79028655
Malignant neoplasm progression 38.06 20.71 71 11890 135919 79596508
Stenotrophomonas infection 38.05 20.71 16 11945 3757 79728670
Aplastic anaemia 38.02 20.71 27 11934 17878 79714549
Drug ineffective 37.97 20.71 284 11677 1080629 78651798
Staphylococcal infection 37.52 20.71 45 11916 58250 79674177
Haematopoietic neoplasm 36.47 20.71 7 11954 87 79732340
Diffuse large B-cell lymphoma recurrent 36.37 20.71 16 11945 4191 79728236
Candida infection 35.92 20.71 36 11925 38178 79694249
Abdominal wall wound 35.83 20.71 7 11954 96 79732331
Colitis 35.28 20.71 49 11912 73258 79659169
Cardiac failure 35.09 20.71 74 11887 154768 79577659
Cystitis haemorrhagic 34.93 20.71 20 11941 9152 79723275
Myeloblast percentage decreased 34.49 20.71 6 11955 41 79732386
Hyperammonaemic encephalopathy 34.41 20.71 16 11945 4766 79727661
Respiratory tract infection fungal 34.31 20.71 11 11950 1202 79731225
Refractory cytopenia with multilineage dysplasia 34.30 20.71 8 11953 263 79732164
Disseminated intravascular coagulation 34.12 20.71 34 11927 35808 79696619
Klebsiella infection 34.07 20.71 24 11937 15696 79716731
Hypertensive hydrocephalus 33.54 20.71 5 11956 10 79732417
Stomatococcal infection 33.36 20.71 8 11953 297 79732130
Pyrexia 32.61 20.71 193 11768 678516 79053911
Chronic lymphocytic leukaemia recurrent 31.86 20.71 9 11952 639 79731788
Pruritus 31.51 20.71 10 11951 394638 79337789
Fall 31.47 20.71 17 11944 487612 79244815
Drug hypersensitivity 31.24 20.71 4 11957 298912 79433515
Hepatic failure 31.09 20.71 42 11919 61170 79671257
Strongyloidiasis 31.05 20.71 14 11947 3884 79728543
Acute lymphocytic leukaemia 30.78 20.71 15 11946 4954 79727473
Nausea 30.65 20.71 61 11900 957135 78775292
Bone marrow infiltration 30.60 20.71 9 11952 737 79731690
Chloroma 30.32 20.71 9 11952 761 79731666
Mucosal inflammation 29.82 20.71 46 11915 75534 79656893
Leukopenia 29.12 20.71 58 11903 116455 79615972
Osteonecrosis 28.68 20.71 29 11932 31066 79701361
Chronic myeloid leukaemia 28.68 20.71 13 11948 3651 79728776
Hepatitis B 28.64 20.71 17 11944 8315 79724112
Pulmonary haemorrhage 28.53 20.71 21 11940 14696 79717731
Acute febrile neutrophilic dermatosis 28.00 20.71 13 11948 3859 79728568
Encephalopathy 27.97 20.71 42 11919 67355 79665072
Dizziness 27.72 20.71 23 11938 526418 79206009
Nasopharyngitis 27.51 20.71 3 11958 253878 79478549
Acute myeloid leukaemia refractory 27.27 20.71 6 11955 151 79732276
Abscess fungal 27.11 20.71 7 11954 353 79732074
Escherichia bacteraemia 26.85 20.71 15 11946 6547 79725880
Aspiration bone marrow abnormal 26.69 20.71 6 11955 167 79732260
Pain in extremity 26.12 20.71 11 11950 364527 79367900
Off label use 26.11 20.71 228 11733 906987 78825440
Pseudomonas infection 25.99 20.71 23 11938 20880 79711547
Blood culture positive 25.88 20.71 16 11945 8413 79724014
Streptococcal bacteraemia 25.74 20.71 12 11949 3594 79728833
Lymphopenia 25.49 20.71 27 11934 30530 79701897
Minimal residual disease 24.73 20.71 7 11954 500 79731927
Hepatitis E 24.67 20.71 11 11950 2975 79729452
Graft versus host disease in gastrointestinal tract 24.58 20.71 14 11947 6342 79726085
Chromosome analysis abnormal 24.42 20.71 6 11955 247 79732180
Weight increased 24.04 20.71 6 11955 277380 79455047
Acute graft versus host disease 23.14 20.71 16 11945 10151 79722276
Portal hypertension 23.12 20.71 14 11947 7094 79725333
Acute myelomonocytic leukaemia 22.95 20.71 6 11955 318 79732109
Cytomegalovirus infection 22.78 20.71 30 11931 42614 79689813
Septal panniculitis 22.46 20.71 5 11956 133 79732294
Pseudomonal sepsis 22.28 20.71 13 11948 6161 79726266
Leukaemic infiltration 22.11 20.71 5 11956 143 79732284
Large granular lymphocytosis 21.95 20.71 6 11955 377 79732050
Diarrhoea 21.90 20.71 64 11897 880425 78852002
Streptococcal sepsis 21.77 20.71 10 11951 2897 79729530
Chromosomal deletion 21.48 20.71 5 11956 163 79732264
Bacterial sepsis 21.29 20.71 14 11947 8184 79724243
Chronic graft versus host disease 21.15 20.71 13 11948 6768 79725659
Pneumonia 21.11 20.71 170 11791 660076 79072351
Chronic myelomonocytic leukaemia 21.04 20.71 7 11954 859 79731568
Cerebral fungal infection 21.03 20.71 6 11955 441 79731986
Metastasis 20.97 20.71 13 11948 6867 79725560
Primary hypogonadism 20.95 20.71 5 11956 182 79732245
Retinal infiltrates 20.89 20.71 4 11957 49 79732378
Parametritis 20.87 20.71 3 11958 4 79732423

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DB07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
FDA MoA N0000000176 Topoisomerase Inhibitors
MeSH PA D000700 Analgesics
MeSH PA D000970 Antineoplastic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D059005 Topoisomerase II Inhibitors
MeSH PA D059003 Topoisomerase Inhibitors
FDA EPC N0000175609 Topoisomerase Inhibitor
CHEBI has role CHEBI:23240 chromophores
CHEBI has role CHEBI:37958 dyes
CHEBI has role CHEBI:76924 plant metabolites
CHEBI has role CHEBI:35610 antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute myeloid leukemia, disease indication 91861009
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378
Metastatic Prostate Carcinoma indication
Follicular non-Hodgkin's lymphoma off-label use 308121000
Metastatic Breast Carcinoma off-label use
Progressive Diffuse Large B-Cell Lymphoma off-label use
Mycosis contraindication 3218000 DOID:1564
Viral disease contraindication 34014006 DOID:934
Chronic heart failure contraindication 48447003
Hepatic failure contraindication 59927004
Acute infectious disease contraindication 63171007
Leukopenia contraindication 84828003 DOID:615
Left heart failure contraindication 85232009
Bacterial infectious disease contraindication 87628006
Radiation oncology AND/OR radiotherapy contraindication 108290001
Acute disease of cardiovascular system contraindication 128487001
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.37 acidic
pKa2 10.7 acidic
pKa3 9.13 Basic
pKa4 8.52 Basic
pKa5 4.01 Basic
pKa6 1.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 2-alpha Enzyme INHIBITOR IC90 5.96 WOMBAT-PK CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.84 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.31 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.73 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.74 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.11 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.05 DRUG MATRIX
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter IC50 6.29 WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter Kact 5.16 WOMBAT-PK
Epidermal growth factor receptor Kinase IC50 5.27 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.90 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.69 DRUG MATRIX
Serine/threonine-protein kinase pim-1 Kinase IC50 7.29 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.36 CHEMBL
DNA-(apurinic or apyrimidinic site) lyase Enzyme IC50 5.70 CHEMBL
Tyrosine-protein kinase BTK Kinase IC50 6 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase IC50 5.52 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.13 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 6.72 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.28 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.22 CHEMBL
DNA-3-methyladenine glycosylase Enzyme IC50 5.60 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.53 DRUG MATRIX
TAR DNA-binding protein 43 Unclassified IC50 5 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.75 DRUG MATRIX
Integrase Enzyme IC50 5.42 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase AC50 5.02 CHEMBL

External reference:

IDSource
4019842 VUID
N0000147929 NUI
D02166 KEGG_DRUG
70476-82-3 SECONDARY_CAS_RN
4019527 VANDF
4019842 VANDF
C0026259 UMLSCUI
CHEBI:50729 CHEBI
MIX PDB_CHEM_ID
CHEMBL58 ChEMBL_ID
CHEMBL1417019 ChEMBL_ID
CHEMBL1200827 ChEMBL_ID
D008942 MESH_DESCRIPTOR_UI
DB01204 DRUGBANK_ID
7242 IUPHAR_LIGAND_ID
4922 INN_ID
BZ114NVM5P UNII
4212 PUBCHEM_CID
203129 RXNORM
5124 MMSL
81184 MMSL
d00306 MMSL
002676 NDDF
004828 NDDF
108791001 SNOMEDCT_US
386913001 SNOMEDCT_US
412249002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4680 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4680 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4685 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4685 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4686 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4686 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 61703-343 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 28 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 61703-343 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 28 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 63323-132 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 15 sections